Results 11 to 20 of about 20,687 (197)

Proton beam therapy in paediatric cancer: Anticipating the opening of the Australian Bragg Centre for Proton Therapy and Research

Journal of Medical Imaging and Radiation Oncology, EarlyView., 2023
Summary Proton Beam Therapy (PBT) has the potential to improve paediatric cancer care by reducing radiation exposure and thus long‐term toxicities. Ethical concerns and debates surrounding the treatment, such as eligibility and accessibility, are ongoing in Australia. The Australian Bragg Centre for Proton Therapy and Research (ABCPTR) (named after Sir
Jeremy Khong, Hui Tee, Peter Gorayski, Hien Le, Michael Penniment, Sophie Jessop, Jordan Hansford, Melanie Penfold, Julia Green, Kelly Skelton, Frank Saran   +10 more
wiley   +1 more source

Chondroitin sulfate proteoglycan 4 expression in chondrosarcoma: A potential target for antibody-based immunotherapy

Frontiers in Oncology, 2022
Chondrosarcoma is a common primary bone malignancy whose phenotype increases with its histologic grade. They are relatively resistant to chemotherapy and radiation therapy limiting curative options for disseminated disease.
Sjoerd P. F. T. Nota, Sjoerd P. F. T. Nota, Sjoerd P. F. T. Nota, David O. Osei-Hwedieh, David O. Osei-Hwedieh, David L. Drum, Xinhui Wang, Francesco Sabbatino, Soldano Ferrone, Joseph H. Schwab, Joseph H. Schwab   +10 more
doaj   +1 more source

The utility of 18F-FDG PET and PET/CT in the diagnosis and staging of chondrosarcoma: a meta-analysis

Journal of Orthopaedic Surgery and Research, 2020
Objective Chondrosarcoma is the second most common primary bone sarcoma; however, unlike other tumors, the biopsy cannot easily make a definite diagnosis or predict the histological grade.
Qingyu Zhang, Yongming Xi, Dong Li, Zenong Yuan, Jun Dong   +4 more
doaj   +1 more source

Gadd45β expression in chondrosarcoma: A pilot study for diagnostic and biological implications in histological grading

Diagnostic Pathology, 2010
Background Although the diagnosis of chondrosarcoma, especially the distinction between enchondroma and low-grade chondrosarcoma or low-grade chondrosarcoma and high-grade chondrosarcoma, is pathologically difficult, differential diagnosis is very ...
Ishido Yasuhiro, Yamamoto Takuya, Nagano Satoshi, Yokouchi Masahiro, Sakakima Harutoshi, Tanimoto Akihide, Zenmyo Michihisa, Komiya Setsuro, Ijiri Kosei   +8 more
doaj   +1 more source

Nerve growth factor promotes lysyl oxidase-dependent chondrosarcoma cell metastasis by suppressing miR-149-5p synthesis

Cell Death and Disease, 2021
Chondrosarcoma is a malignancy of soft tissue and bone that has a high propensity to metastasize to distant organs. Nerve growth factor (NGF) is critical for neuronal cell growth, apoptosis, and differentiation, and also appears to promote the ...
Huey-En Tzeng, Syuan-Ling Lin, Louis Anoop Thadevoos, Ming-Yu Lien, Wei-Hung Yang, Chih-Yuan Ko, Chih-Yang Lin, Yu-Wen Huang, Ju-Fang Liu, Yi-Chin Fong, Hsien-Te Chen, Chih-Hsin Tang   +11 more
doaj   +1 more source

Elevated levels of Dickkopf-1 are associated with β-catenin accumulation and poor prognosis in patients with chondrosarcoma. [PDF]

PLoS ONE, 2014
BACKGROUND: Dickkopf-1 (DKK1) is an antagonist of Wnt/β-catenin signaling implicated in tumorigenesis. However, the biological role of DKK1 and β-catenin involved in chondrosarcoma has not been sufficiently investigated.
Changbao Chen, Hua Zhou, Xiaolin Zhang, Xinlong Ma, Zhongjun Liu, Xiaoguang Liu   +5 more
doaj   +1 more source

CXCR4/SDF1 mediate hypoxia induced chondrosarcoma cell invasion through ERK signaling and increased MMP1 expression

Molecular Cancer, 2010
Background Chondrosarcoma is a disease that does not respond to conventional cytotoxic chemotherapy and expression of MMP1 is a marker for a poor prognosis. The mechanism of increased MMP1 expression in chondrosarcoma is not completely known. Our goal is
Chen Qian, Wei Lei, Sun Xiaojuan, Terek Richard M   +3 more
doaj   +1 more source

Late Lung Metastasis in a Patient with a Clear Cell Chondrosarcoma: An Indication for a Life-Long Follow-Up?

Case Reports in Oncological Medicine, 2021
Background. Clear cell chondrosarcoma (CCCS) is a rare subtype of chondrosarcoma and comprises between 1.6% and 2.5% of all chondrosarcoma. They are known to be chemo- and radiotherapy resistant; surgical resection is therefore the therapy of choice ...
Paulien West, Celine Jacobs, Michael Saerens, David Creytens, Gwen Sys, Lore Lapeire   +5 more
doaj   +1 more source

The antiapoptotic gene survivin is highly expressed in human chondrosarcoma and promotes drug resistance in chondrosarcoma cells in vitro

BMC Cancer, 2011
Background Chondrosarcoma is virtually resistant to chemotherapy and radiation therapy. Survivin, the smallest member of the inhibitor of apoptosis protein family, is a critical factor for tumor progression and resistance to conventional therapeutic ...
Grifka Joachim, Tingart Markus, Balakrishnan Sanjeevi, Campean Valentina, Renkawitz Tobias, Lechler Philipp, Schaumburger Jens   +6 more
doaj   +1 more source

A screening-based approach identifies cell cycle regulators AURKA, CHK1 and PLK1 as targetable regulators of chondrosarcoma cell survival

Journal of Bone Oncology, 2019
Chondrosarcomas are malignant cartilage tumors that are relatively resistant towards conventional therapeutic approaches. Kinase inhibitors have been investigated and shown successful for several different cancer types.
Yvonne de Jong, Fairuz Bennani, Jolieke G. van Oosterwijk, Gaia Alberti, Zuzanna Baranski, Pauline Wijers-Koster, Sanne Venneker, Inge H. Briaire-de Bruijn, Brendy E. van de Akker, Hans Baelde, Anne-Marie Cleton-Jansen, Bob van de Water, Erik H.J. Danen, Judith V.M.G. Bovée   +13 more
doaj   +1 more source